SCHEMBL6404812

SCHEMBL6404812

COc1ccc(NS(=O)(=O)CN(CCCc2ccccc2)C(=O)CC(C)CCNC(=O)c2cccc(NC(=O)OC(C)(C)C)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
NAMPT P43490 1/20 0.39
SENP1 Q9P0U3 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
KAT6A Q92794 1/20 0.38
LMNA P02545 4/20 0.38
SIGMAR1 Q99720 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MITF O75030 1/20 0.37
KMT2A Q03164 1/20 0.36
PAX8 Q06710 1/20 0.36
HPGD P15428 1/20 0.36
OPRK1 P41145 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2B6 P20813 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6409458 0.92 NPC1 (0.42) NPC1RAB9ANAMPTSENP1LMNA
SCHEMBL6401375 0.89 NPC1 (0.39) NPC1RAB9ALMNASIGMAR1SMN1; SMN2
SCHEMBL6405210 0.87 NPC1 (0.43) NPC1RAB9ANAMPTLMNASIGMAR1
SCHEMBL6401317 0.83 NPC1 (0.47) NPC1RAB9ANAMPTLMNASIGMAR1
SCHEMBL6401362 0.83 RAB9A (0.45) NPC1RAB9ANAMPTSIGMAR1KMT2A
SCHEMBL6403180 0.83 MMP3 (0.42) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL6404808 0.82 CASR (0.37) KAT6ALMNASMN1; SMN2KMT2AHPGD
SCHEMBL6407167 0.81 CA1 (0.42) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL6403803 0.78 KMT2A (0.45) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL6403042 0.77 HTT (0.41) RAB9ALMNAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 NPC1 972/4885RAB9A 2791/4885NAMPT 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.